Zevra Therapeutics (ZVRA) Gross Profit (2019 - 2026)

Zevra Therapeutics (ZVRA) has 7 years of Gross Profit data on file, last reported at $34.3 million in Q1 2026.

• Quarterly Gross Profit rose 80.13% year-over-year to $34.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $105.3 million (up 229.89% YoY) and the FY2025 annual result came in at $90.0 million, up 455.65% from the prior year.
• Gross Profit improved to $34.3 million in Q1 2026, from $32.6 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $34.3 million in Q1 2026 to a low of -$8000.0 in Q1 2022.
• A 5-year average of $10.1 million and a median of $3.2 million in 2024 frame the typical range for Gross Profit.
• Annual changes were most pronounced in 2023 — Gross Profit soared 38237.5% — and 2024, when it tumbled 89.39%.
• Tracing ZVRA's Gross Profit over 5 years: stood at $1.9 million in 2022, then soared by 505.85% to $11.7 million in 2023, then decreased by 8.95% to $10.6 million in 2024, then surged by 206.69% to $32.6 million in 2025, then gained by 5.12% to $34.3 million in 2026.
• The last three Gross Profit figures came in at $34.3 million (Q1 2026), $32.6 million (Q4 2025), and $24.8 million (Q3 2025), per Business Quant data.